Home › Chronic Subdural Hematoma › NCT06181994

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

RecruitingObservational study

Outcomes of Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma; Middle Meningeal Artery Embolization for Chronic Subdural Hematoma (MESH)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Consecutive adult patients (18 yrs. of age or older)
* Endovascular embolization of middle meningeal artery using any embolization material:

PVA particles; Onyx, N-butyl cyanoacrylate (nBCA) glue; dimethyl sulfoxide, microcoils, polyvinyl alcohol (PVA) with microcoils

Exclusion Criteria:

* Endovascular embolization of middle meningeal artery using any other embolization material

About the study

This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.

Sponsor: Montefiore Medical Center · Participants: 5,000 · Started: Dec 5, 2023

Contact the study team

Muhammed Amir Essibayi, MD · Phone: 347-908-1889

Official record on ClinicalTrials.gov — NCT06181994

Locations in the U.S.

Florida	Baptist Health South Florida, Inc., Coral Gables University of Miami, Miami Orlando Regional Medical Center, Orlando
Illinois	University of Chicago Medicine, Chicago
Massachusetts	Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School, Boston Massachusetts General Hospital, Boston Lahey Hospital and Medical Center, Burlington
Minnesota	Allina Health, Minneapolis
New York	Montefiore Medical Center, The Bronx
Pennsylvania	Thomas Jefferson University, Philadelphia
West Virginia	West Virginia University, Morgantown

Conditions

Chronic Subdural Hematoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.